Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants

BackgroundAntibody–drug conjugates (ADC), such as enfortumab vedotin (EV), sacituzumab govitecan (SG), and RC-48, have shown outstanding response rates to local advanced or metastatic urothelial carcinoma (UC). However, their corresponding target expression characteristics in UC and its histologic v...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yu Fan, Qinhan Li, Qi Shen, Zhifu Liu, Zhenan Zhang, Shuai Hu, Wei Yu, Zhisong He, Qun He, Qian Zhang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-04-01
coleção:	Frontiers in Oncology
Assuntos:	urothelial carcinoma ADC nectin-4 Trop-2 HER2 histologic variants
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fonc.2022.858865/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!